Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 10/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 10/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 9/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 9/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576737 | 0.90 | GRIN1 (0.82) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4552245 | 0.85 | GRIN2D (0.83) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4577807 | 0.85 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4421110 | 0.84 | GRIN1 (0.83) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4963464 | 0.83 | GRIN1 (0.71) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4414773 | 0.82 | GRIN2D (0.83) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4578469 | 0.80 | GRIN1 (0.71) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL1384919 | 0.79 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4578171 | 0.78 | GRIN1 (0.72) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4414751 | 0.77 | GRIN2D (0.68) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4322113-B2 | — | — | 2009-08-26 | — | — | JP | claimed |
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | claimed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | claimed |
| JP-2005515968-A | — | — | 2005-06-02 | — | — | JP | claimed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | claimed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | claimed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | claimed |
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | GRIN1 1/4885GRIN2B 7/4885GRIN2D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.